Efficacy of Flumatinib in CML Patients with F359V/C Mutation

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• BCR-ABL mutations cause tyrosine kinase inhibitor (TKI) resistance in chronic myelocytic leukemia (CML).
• Second-generation TKIs like dasatinib and nilotinib have limitations against specific mutants.
• Adverse events from TKIs often lead to treatment discontinuation and reduced quality of life.

Purpose of the Study:

• To evaluate the efficacy of flumatinib in CML patients with the F359V/C mutation, a mutation not previously studied.
• To compare the safety and tolerability of flumatinib with other TKIs in this patient population.

Main Methods:

• Case report of two CML patients with F359V/C mutation resistant to imatinib.
• One patient was treated with dasatinib, experiencing significant adverse events.
• Two patients were subsequently treated with flumatinib.

Main Results:

• Flumatinib treatment led to major molecular remission (MR4) and undetectable F359V/C mutation.
• Patients treated with flumatinib experienced minimal adverse events (grade 1 or 2) and maintained a high quality of life.
• Dasatinib treatment in one patient resulted in severe adverse events (pleural effusion, anemia), necessitating dose reduction.

Conclusions:

• Flumatinib demonstrates significant efficacy against the F359V/C mutation in CML.
• Flumatinib offers a favorable safety profile with fewer adverse reactions compared to other TKIs.
• Flumatinib may represent a superior treatment option for CML patients harboring the F359V/C mutation.